Genmab — Marts 2017
-
@ Mscotland. Kyprolis (carfilzomib) er en protesomhæmmer ligesom Velcade (bortezomib). Disse to var sat op imod hinanden i et fase 3 studie, som faldt ud til Kyprolis' fordel http://wwwext.amgen.com/media/news-releases/2017/02/phase-3-headtohead-trial-showed-kyprolis-carfilzomib-significantly-improved-overall-survival-compared-to-velcade-bortezomib-in-relapsed-or-refractory-multiple-myeloma-patients/ . Heldigvis for det, for det betyder at kombinationen med dara og en proteasomhæmmer blot bliver
-
-
haha
-
GlobalMacro: I disagree. Many CEO's have been driving it much, much longer. Look e.g. on Steve Balmer (former CEO of Microsoft). ...but the risk that he or his key employees one day will stop because the have enough money is real. One the upside is however, that Independent people stand up for what they belive and only work fore what they Think give sence,
-
Godmorgen.
-
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind